End of June 2016 Algiax started a collaboration program to perform a preclinical Proof-of-Concept in Diabetes Type 1 with a selection of Algiax` proprietary new chemical entities.

On December 10th 2015 Algiax got its approval from the German authorities (BfArM) to start the Phase Ib study entitled “Pharmacodynamic Effects of AP-325 in Healthy Male Subjects using the Intradermal (ID) Capsaicin and Pressure Pain Models”.

Today Algiax announces the completion of two successful Phase I trials with their lead compound AP-325. AP-325 was tested in both single and multiple dose studies in healthy volunteers. In the two clinical studies AP-325 was shown to be safe and well tolerated and the aimed exposure levels with the oral formulation have been reached.

As of June 2015, Algiax initiated a Phase I study with the primary objective to investigate the pharmacokinetics, safety, and tolerability of multiple ascending doses of AP-325 in healthy male subjects.

As of November 2014, Algiax initiated a Phase I study with the primary objective to investigate the pharmacokinetics, safety, and tolerability of single ascending doses of AP-325 in healthy male subjects. In addition, Algiax aimed to investigate the influence of food, gender and age on the safety, tolerability, and pharmacokinetics of a single oral dose of AP-325.

In August 2013 our lead compound AP-325 received Orphan Drug Designation from EMA for the treatment of traumatic spinal cord injury.

In January 2012 a Series A investment of 4.3M€ was closed.